Skip to main content

Anakinra May Attenuate Stroke Outcomes

The journal Stroke has published a trial wherein the use of subcutaneous IL-1Ra (anakinra) was shown to reduce the peripheral inflammatory response in those with an acute ischemic stroke. (Citation source: http://bit.ly/2uoNXEL)

Based on data showing worse stroke outcomes in the face of high IL-6 and C-reactive protein (CRP) levels, researchers sought to assess whether control of inflammation post-CVA would limit cerebral ischemia and improve outcomes after ischemic stroke. 

A double-blind, randomized, placebo-controlled phase 2 trial of subcutaneous anakinra (100 mg given twice daily for 3 days) was initiated within 5 hours of ischemic stroke onset.  The primary outcome was difference in concentration of log(interleukin-6) as area under the curve to day 3. Secondary outcomes included the 3-month stroke outcome assessed by modified Rankin Scale.

A total of 80 patients (mean age, 72 years) were enrolled and 73% received intravenous thrombolytic therapy. Patients were then treated with either placebo or anakinra bid for 3 days.  After 3 days the anakinra patients had significantly lower plasma interleukin-6 (P<0.001) and plasma C-reactive protein (P<0.001) levels.

Despite being well tolerated with no safety concerns, anakinra lowered the modified Rankin Scale, but this was not significant (OR=0.67; (0.29–1.52), P=0.34).

These insufficient 3 mos clinical outcomes may relate to the relatively short duration of anakinra therapy and other factors.  Yet these data suggest the potential interplay between inflammation (IL-1) and tissue damage from thrombotic events. 

These data follow a recent Lancet report of the CANTOS study showing cannakinumab (IL-1 inhibition) significantly lower rate of recurrent cardiovascular events (in high-risk CV patients); and at the same time reduce the rate of total cancer deaths, especially lung cancer. 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject